Single dose open-label comparative pharmacokinetic study to assess the pharmacokinetic characteristics of Irbesartan and Atorvastatin between Irbesartan/Atorvastatin combination tablet and coadministration of Irbesartan and Atorvastatin tablets in healthy male subjects : Irbesartan 150mg and Atorvastatin 20mg.

Trial Profile

Single dose open-label comparative pharmacokinetic study to assess the pharmacokinetic characteristics of Irbesartan and Atorvastatin between Irbesartan/Atorvastatin combination tablet and coadministration of Irbesartan and Atorvastatin tablets in healthy male subjects : Irbesartan 150mg and Atorvastatin 20mg.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs Atorvastatin/irbesartan (Primary) ; Atorvastatin; Irbesartan
  • Indications Heart failure; Hypercholesterolaemia; Hypertension; Hypertriglyceridaemia; Low HDL cholesterol
  • Focus Pharmacokinetics
  • Acronyms HM-IBAT-301
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 02 Apr 2012 Actual patient number added 52 according to ClinicalTrials.gov.
    • 02 Apr 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 02 Apr 2012 Status changed from recruiting to completed 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top